Publications by authors named "Dieudonne Ekoukou"
Article Synopsis
- The study highlights the involvement of angiogenic factors (like sFlt-1, PlGF, and VEGF) in the development and diagnosis of preeclampsia, emphasizing their importance in understanding the condition since the early 2000s.
- It suggests that the sFlt-1/PlGF ratio is a useful tool for assessing preeclampsia risk and effectiveness of treatments in the second and third trimesters, with specific cutoff values indicating diagnosis and prognosis.
- The identification of angiogenic versus non-angiogenic preeclampsia based on the sFlt-1/PlGF ratio may lead to improved clinical management and safety for mothers and fetuses, potentially influencing future medical guidelines
Lopinavir/ritonavir monotherapy as a nucleoside analogue-sparing strategy to prevent HIV-1 mother-to-child transmission: the ANRS 135 PRIMEVA phase 2/3 randomized trial.
Clin Infect Dis
September 2013
Background: Prevention of mother-to-child transmission (PMTCT) of human immunodeficiency virus (HIV) is usually based on zidovudine-containing regimens, despite potential toxicities. This multicenter trial evaluated whether lopinavir/ritonavir (LPV/r) monotherapy in HIV type 1-infected women not requiring antiretrovirals for themselves could control maternal viral load (VL).
Methods: Overall, 105 pregnant women with baseline VL <30 000 copies/mL and CD4 ≥350 cells/µL were randomized to start open-label LPV/r 400/100 mg twice daily alone (monotherapy group, n = 69) or combined with zidovudine/lamivudine 300/150 mg twice daily (triple therapy group, n = 36) from 26 gestational weeks to delivery.
Background: The association between combination antiretroviral (cARV) therapy use by human immunodeficiency virus (HIV)-infected women during pregnancy and risk of prematurity is still controversial. We explored this question, focusing on the initiation of ritonavir-boosted protease inhibitors (PIs) during pregnancy, which is now standard care.
Methods: Trends in prematurity (<37 gestational weeks) were studied among all singleton pregnancies in the Agence Nationale de Recherche sur le SIDA (ANRS) French Perinatal Cohort from 1990 through 2009 (n = 13 271).
Objective: The objective of the study was to investigate whether performing an amniocentesis increased mother-to-child transmission of human immunodeficiency virus (HIV)-1 (MTCT).
Study Design: We studied HIV -1 infected mothers and their children enrolled in the multicenter French Perinatal HIV Cohort from 1985 to 2006.
Results: One hundred sixty-six amniocenteses were performed among 9302 singleton pregnancies, the proportion increasing from 1.
Objectives: To assess the risk of vertical transmission in HIV-infected pregnant women undergoing diagnostic amniocentesis, and to identify possible predictive factors.
Study Design: This was a single center retrospective study. The records of 330 HIV-infected pregnant women booked in our antenatal clinic from 31 January 2001 to 31 January 2006 were analyzed.